Skip to content

Envoy Medical COCH Income Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$39K-48.0%$75K+78.6%$42K-46.2%$78K+69.6%$46K+9.5%
$313K+48.3%$211K+3.9%$203K-13.2%$234K+3.5%$226K+43.9%
-$274K-101%-$136K+15.5%-$161K-3.2%-$156K+13.3%-$180K-56.5%
-702.6%-521pp-181.3%+202pp-383.3%-183pp-200%+191pp-391.3%-117pp
$3.64M-20.0%$4.55M+68.6%$2.7M+8.7%$2.49M-9.6%$2.75M+11.2%
$164K+70.8%$96K-76.3%$405K+12.2%$361K+0.8%$358K-30.9%
$1.88M+17.4%$1.6M-34.5%$2.44M+18.1%$2.07M+13.6%$1.82M+26.0%
$6M-7.2%$6.46M+12.3%$5.75M+11.7%$5.15M-0.1%$5.15M+12.2%
-$5.96M+6.7%-$6.39M-11.9%-$5.71M-12.6%-$5.07M+0.7%-$5.11M-12.3%
-15,279.5%-6,766pp-8,513.3%+5,077pp-13,590.5%-7,090pp-6,500%+4,602pp-11,102.2%-271pp
$0-100%$471K-24.5%$624K+26.1%$495K+28.9%
$1.61M+900%-$201K+74.0%-$774K-24.8%-$620K-669%$109K+258%
-$4.35M+33.9%-$6.59M-1.6%-$6.48M-13.9%-$5.69M-13.8%-$5M-8.2%
-11,156.4%-2,375pp-8,781.3%+6,652pp-15,433.3%-8,138pp-7,294.9%+3,570pp-10,865.2%+130pp
-$0.08+69.2%-$0.26+25.7%-$0.35-9.4%-$0.32-10.3%-$0.29+27.5%
-$5.89M+6.6%-$6.31M-11.9%-$5.63M-13.0%-$4.99M+1.2%-$5.05M-12.1%
-15,092.3%-6,686pp-8,406.7%+5,003pp-13,409.5%-7,018pp-6,391%+4,579pp-10,969.6%-253pp
-$5.96M+6.7%-$6.39M-11.9%-$5.71M-12.6%-$5.07M+0.7%-$5.11M-12.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Envoy Medical's revenue?
Envoy Medical (COCH) generated $234.0K in revenue over the trailing twelve months, up 10.4% year over year.
Is Envoy Medical profitable?
Envoy Medical is not currently profitable: it reported a net loss of $23.1M over the trailing twelve months, a -9875.6% net margin.
What are Envoy Medical's profit margins?
Gross margin is -310.7% and operating margin is -9881.2%, with a -9875.6% net margin.
What is Envoy Medical's earnings per share?
Envoy Medical's diluted EPS over the trailing twelve months is $-1.01.
Where does Envoy Medical's income statement data come from?
Every line is extracted from Envoy Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.